#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute on chronic liver failure Hyperchylomicronaemia B-cell small lymphocytic lymphoma Acute promyelocytic leukaemia Testicular leiomyosarcoma Non-small cell lung cancer Bone marrow disorder Cerebellar ataxia Plasma cell myeloma Myelofibrosis Chronic cutaneous lupus erythematosus Extra-osseous Ewing's sarcoma Liposarcoma recurrent Gaucher's disease type I Colitis ulcerative More trials…

    Learn about Rare Diseases

    Lysosomal storage disorder – Life with Disease Mantle cell lymphoma stage IV – Life with Disease Gastrointestinal stromal tumour – Treatment Nephroblastoma – Basic Information Hereditary neuropathic amyloidosis – Basic Information Urea cycle disorder – Trials in Disease Methylmalonic acidaemia – Basic Information Amyotrophic lateral sclerosis Leiomyosarcoma recurrent – Basic Information Prader-Willi syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sulfamethoxazole Aon-D21 Asundexian Gtaexs617 Edoxaban Cefoxitin Sodium Ramipril Meropenem Crovalimab Hypothalamic Phospholipids Triptorelin Acetate 12 Grass Pollen Mixture Blu-451 Tocotrienol Bbp-398 Utreloxastat HYDROMORPHONE HYDROCHLORIDE Pervi-Fus Dipyridamole Deferoxamine Mesilate More therapies…

    Learn about Your Condition

    Naevoid melanoma Neuralgia Intermittent claudication Psychotic disorder Anxiety disorder Lung disorder Angiopathy Coronary artery occlusion Dyskinesia Vulvovaginal discomfort Lymphocyte adoptive therapy Cervix carcinoma recurrent Electronic cigarette user Mucopolysaccharidosis III Oesophageal atresia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastric cancer
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Zolbetuximab
    • Azd0901
    • Capecitabine
    Belgium France Germany Hungary Italy The Netherlands +2

  • Phase 1/2 Study of CR-001 Safety and Dose Finding in Adults with Locally Advanced or Metastatic Solid Tumors

    Recruiting

    2 1 1
    France Ireland Italy Romania Spain

  • Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Factor VIII deficiency
    Investigated Drugs:
    • Emicizumab
    • Ro7589655
    Austria Belgium Denmark France Germany Hungary +5

  • A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Simoctocog Alfa
    • Ro7589655
    Austria Denmark France Germany Hungary Italy +3

  • Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

    Recruiting

    2 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Ro7790121
    Belgium Denmark France Germany Italy Poland +1

  • Study of MK-1045 alone or with Tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Tocilizumab
    France Germany Italy Poland Spain

  • Efficacy and safety of GB-0895 as adjunctive therapy in adults and adolescents with severe uncontrolled asthma (randomized, placebo‑controlled)

    Recruiting

    3 1
    Belgium Estonia France Ireland Italy Slovakia +1

  • A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    • Risankizumab
    Austria Belgium Czechia Denmark France Germany +7

  • INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Calcium Folinate
    • Bevacizumab
    • Fluorouracil
    Austria Belgium Denmark France Germany Italy +4

  • Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    3 1
    Investigated Drugs:
    • Nipocalimab
    Bulgaria Czechia Denmark Finland France Germany +9
Previous Page
1 2 3 4 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!